Synteract snaps up pediatric CRO KinderPharm for undisclosed price

Children's Hospitals
Synteract acquired specialty pediatric CRO KinderPharm for an undisclosed price, expanding its reach in the pediatrics arena. (GeorgeRudy)

San Diego and North Carolina-based Synteract has acquired specialty pediatric CRO KinderPharm for an undisclosed price.

KinderPharm, which is based in Pennsylvania, focuses on advanced pharmacometric modeling and clinical trial simulation technology as well as providing juvenile formulation and toxicology services.

Financial terms of the deal weren’t disclosed.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

As part of the acquisition, KinderPharm’s founder and chief executive, Martin Graham, Ph.D., becomes senior vice president of pediatric development and global leader for the company’s Center of Pediatric Development. He is being joined by Lynne Georgopoulos, who was named vice president of pediatric development for the Americas. Synteract’s Dr. Martine Dehlinger-Kremer, Ph.D., will support the effort as vice president of pediatric development for Europe.

“We are now integrating Synteract’s existing base of experience and leadership with the focused knowledge and expertise that KinderPharm has provided its clients for many years,” Steve Powell, Synteract’s chief executive, said in a statement. “Together we become the leading CRO for pediatric services, delivery a single source model for preclinical and clinical development, along with the specialized operational and logistical understanding required in working with children and their families.”

Earlier this year, Synteract snapped up specialty contract researcher Cu-Tech for an undisclosed price. That deal was part of Synteract’s move to create a dedicated center for the development of dermatology products and establish itself as a destination for skin-care clinical trials.